Emerging treatments for chronic urticaria

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Abdul Latiff AH, and Abuzakouk M, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021.
   Google Scholar
• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–432.
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9(6):2195–2208.
   PubMed Web of Science ®Google Scholar
• Kay AB, Clark P, Maurer M, et al. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol. 2015;172(5):1294–1302.
   PubMedGoogle Scholar
• Maurer M, Khan DA, Elieh Ali Komi D, et al. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9(3):1067–1078.
   PubMed Web of Science ®Google Scholar
• Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694–700.
   PubMed Web of Science ®Google Scholar
• Oliver ET, Sterba PM, Saini SS. Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria. Allergy. 2015;70(5):601–603.
   PubMedGoogle Scholar
• Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract. 2020;8(1):318–325.e5.
   PubMed Web of Science ®Google Scholar
• Grattan CE, Dawn G, Gibbs S, et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003;33(3):337–341.
   PubMedGoogle Scholar
• Asero R, Cugno M. Biomarkers of chronic spontaneous urticaria and their clinical implications. Expert Rev Clin Immunol. 2021;17(3):247–254.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519–533.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–1781.e1.
   PubMed Web of Science ®Google Scholar
• Goncalo M, Gimenez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226–236.
   PubMed Web of Science ®Google Scholar
• Johansson S. Milestones in understanding allergy and its diagnosis. Clin Exp Allergy Rev. 2002;2(1):2–7.
   Google Scholar
• Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy. 1999;29(Suppl 3):1–11. discussion 12.
   PubMedGoogle Scholar
• Wedi B, Traidl S. Anti-IgE for the treatment of chronic urticaria. Immunotargets Ther. 2021;10:27–45.
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (Spontaneous) urticaria: a meta-analysis of “Real-world” evidence. JAMA Dermatol. 2019;155(1):29–38.
   PubMed Web of Science ®Google Scholar
• Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol. 2018;141(5):1726–1734.
   PubMed Web of Science ®Google Scholar
• Wedi B. Contemporary grand challenges and opportunities in skin allergies. Front Allergy. 2021;2:4.
   Google Scholar
• Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173(2):404–415.
   PubMed Web of Science ®Google Scholar
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750.e4.
   PubMed Web of Science ®Google Scholar
• Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI biologicals guidelines. Allergy. 2021;76(1):59–70.
   PubMed Web of Science ®Google Scholar
• Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649.
   PubMed Web of Science ®Google Scholar
• Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154(2):177–180.
   PubMed Web of Science ®Google Scholar
• Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol. 2021;184(1):167–168.
   PubMedGoogle Scholar
• Metz M, Bergmann P, Zuberbier T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(2):247–249.
   PubMed Web of Science ®Google Scholar
• Metz M, Schutz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):864–867.e5.
   PubMed Web of Science ®Google Scholar
• Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117(6):1415–1418.
   PubMed Web of Science ®Google Scholar
• Bullerkotte U, Wieczorek D, Kapp A, et al. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65(7):931–932.
   PubMed Web of Science ®Google Scholar
• Guzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(11):1563–1565.
   PubMed Web of Science ®Google Scholar
• Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010;65(11):1494–1495.
   PubMedGoogle Scholar
• Maurer M, Schutz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):870–873.e5.
   PubMed Web of Science ®Google Scholar
• Bindslev-Jensen C, and Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65(1):138–139 .
   PubMedGoogle Scholar
• Deza G, March-Rodriguez A, Sanchez S, et al. Relevance of the basophil high-affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution. J Allergy Clin Immunol Pract. 2019;7(5):1619–1626.e1.
   PubMed Web of Science ®Google Scholar
• Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin. Theranostics. 2017;7(5):1266–1276.
   PubMedGoogle Scholar
• Gomez G. Current strategies to inhibit high affinity FcepsilonRI-Mediated signaling for the treatment of allergic disease. Front Immunol. 2019;10:175.
   PubMed Web of Science ®Google Scholar
• Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium Internationale Allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(5):321–333.
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Schmetzer O, et al. Immunoglobulin E-mediated autoimmunity. Front Immunol. 2018;9:689.
   PubMed Web of Science ®Google Scholar
• Kocatürk E, Deza G, Kızıltaç K, et al. Omalizumab updosing for better disease control in chronic spontaneous urticaria patients. Int Arch Allergy Immunol. 2018;177(4):360–364.
   PubMedGoogle Scholar
• Metz M, Vadasz Z, Kocaturk E, et al. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45.
   PubMed Web of Science ®Google Scholar
• Curto-Barredo L, Spertino J, Figueras-Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol. 2018;179(1):210–212.
   PubMedGoogle Scholar
• Türk M, Carneiro-Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–124.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Jensen RK, Jabs F, Miehe M, et al. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy. Allergy. 2020;75(8):1956–1965.
   PubMed Web of Science ®Google Scholar
• Gasser P, Eggel A. Targeting IgE in allergic disease. Curr Opin Immunol. 2018;54:86–92.
   PubMed Web of Science ®Google Scholar
• Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun. 2016;7:11610.
   PubMed Web of Science ®Google Scholar
• Selb R, Eckl-Dorna J, Twaroch TE, et al. Critical and direct involvement of the CD23 stalk region in IgE binding. J Allergy Clin Immunol. 2017;139(1):281–289.e5.
   PubMed Web of Science ®Google Scholar
• Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975–9987.
   PubMed Web of Science ®Google Scholar
• Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321–1332.
   PubMed Web of Science ®Google Scholar
• Wedi B. Ligelizumab for the treatment of chronic spontaneous urticaria. Expert Opin Biol Ther. 2020;20(8):853–861.
   PubMed Web of Science ®Google Scholar
• Maurer M, Giménez-Arnau A, Bernstein JA, et al. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study. Allergy. 2021. DOI:https://doi.org/10.1111/all.15175.
   Google Scholar
• Soong W, Lanier B, Sitz K, et al. Ligelizumab achieves sustained control of angioedema in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2019;123(5):S27.
   Google Scholar
• Sitz K, Soong B, Lanier K, et al. Ligelizumab reduces rescue medication use in patients with chronic spontaneous urticaria: phase 2B study results. Ann Allergy. 2019;123(5):S28.
   Google Scholar
• Severin T, Maurer M, and Giménez-Arnau AM, et al. Study design and rationale of a phase 3b extension study of ligelizumab in adult and adolescent patients with chronic spontaneous urticaria. Allergy 2020;75(S109):446.
   PubMedGoogle Scholar
• Shiung YY, Chiang CY, Chen JB, et al. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors. Immunobiology. 2012;217(7):676–683.
   PubMed Web of Science ®Google Scholar
• Chen JB, Ramadani F, Pang MOY, et al. Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody. Sci Rep. 2018;8(1): 11548–4. DOI:https://doi.org/10.1038/s41598-018-29664-4.
   Google Scholar
• Derbyshire M. Patent expiry dates for biologicals: 2016 update. Gabi J Generics Biosimilars Initiative J. 2017;6(1):27–30.
   Google Scholar
• Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges. 2018;16(4):477–478.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204(2):253–258.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar
• Taleb AA, Badgett RG. In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y. Ann Intern Med. 2021;174(10): JC115–115. Epub 2021 Oct 5. DOI:https://doi.org/10.7326/ACPJ202110190-115.
   Google Scholar
• Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol. 2019;33(11): e413-e415. DOI:https://doi.org/10.1111/jdv.15720.
   Google Scholar
• Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria. N Engl J Med. 2020;383(14):1389–1391.
   PubMedGoogle Scholar
• Bernstein JA, Singh U, Rao MB, et al. Treatment of chronic spontaneous urticaria with benralizumab: report of primary endpoint per-protocol analysis and exploratory endpoints. Allergy. 2021;76(4):1277–1280.
   PubMedGoogle Scholar
• Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204.
   PubMed Web of Science ®Google Scholar
• Maurer M, Crew L, Murphy M, et al. CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in serum tryptase and a favorable safety profile in a phase 1a healthy volunteer study. Allergy. 2020;75:280.
   Google Scholar
• Terhorst-Molawi D, Hawro T, Grewkowitz E, et al. The anti-KIT antibody, CDX-0159, reduces disease activity and tryptase levels in patients with chronic inducible urticaria. Allergy. 2021;76(Suppl. 110):651.
   Google Scholar
• Weber ANR, Bittner Z, Liu X, et al. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57–z.
   PubMedGoogle Scholar
• Estupiñán HY, Berglöf A, Zain R, et al. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.
   PubMed Web of Science ®Google Scholar
• Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2020;63(10):5102–5118.
   PubMedGoogle Scholar
• Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756–1768.
   PubMedGoogle Scholar
• Wedi B. Bruton tyrosine kinase inhibition in dermatology and allergology. Hautarzt. 2018;69(6):519–522.
   PubMedGoogle Scholar
• Smiljkovic D, Blatt K, Stefanzl G, et al. BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils. Allergy. 2017;72(11):1666–1676.
   PubMedGoogle Scholar
• Dispenza MC. The use of Bruton’s tyrosine kinase inhibitors to treat allergic disorders. Curr Treat Options Allergy. 2021;8(3):261–273.
   PubMedGoogle Scholar
• Maurer M, et al. The Bruton’s tyrosine kinase inhibitor remibrutinib (LOU064) in chronic spontaneous urticaria: top line results of a phase 2b dose-finding study. Presented at the EADV Congress 2021 29.09.2021-2.10.2021 Virtual. 2021.
   Google Scholar
• Langrish CL, Bradshaw JM, Francesco MR, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454–1468.
   PubMedGoogle Scholar
• Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27(11):1961–1969.
   PubMed Web of Science ®Google Scholar
• Chen G, Zhao J, and Chen T, et al. Efficacy and safety of Xiaofeng powder (xiao feng san) in treating urticaria: a protocol for a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(45):e13039.
   PubMedGoogle Scholar
• Kavati A, Zhdanava M, Ortiz B, et al. Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. Allergy Asthma Proc. 2019;40(5):321–328.
   PubMedGoogle Scholar
• McIntyre AP, Viswanathan RK, Moss MH, et al. Real-world dosing of omalizumab for chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2020;124(2):211–212.
   PubMedGoogle Scholar
• Nochaiwong S, Chuamanochan M, Ruengorn C, et al. Evaluation of Pharmacologic Treatments for H 1 Antihistamine–Refractory Chronic Spontaneous Urticaria. JAMA Dermatol. 2021;157:1316.
   PubMedGoogle Scholar
• Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol. 2020;38(1):49–77.
   PubMedGoogle Scholar
• Jiménez M, Cervantes-García D, Córdova-Dávalos LE, et al. Responses of mast cells to pathogens: beneficial and detrimental roles. Front Immunol. 2021;12:685865.
   PubMedGoogle Scholar
• Dahlin JS, Maurer M, and Metcalfe DD, et al. The ingenious mast cell: contemporary insights into mast cell behavior and function. Allergy;2022;77(1): 83–99 .
   PubMedGoogle Scholar
• Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 2006;126(5):1102–1110.
   PubMedGoogle Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H 1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–1144.
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: x-ACT study data. Allergy. 2018;73(3):576–584.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M. How to control recurrent angioedema using monoclonal antibody therapies? Expert Opin Biol Ther. 2020;20(1):1–4.
   PubMed Web of Science ®Google Scholar
• Yamani A, Wu D, Waggoner L, et al. The vascular endothelial specific IL-4 receptor alpha–ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions. J Allergy Clin Immunol. 2018;142(4):1159–1172. e5.
   PubMedGoogle Scholar